Bo Peng

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Adriana E. Tron, Matthew A. Belmonte, Ammar Adam et al. · Nature Communications · 2018 · 479 citations · Full text

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

Jianming Xu, Haiping Jiang, Yueyin Pan et al. · JAMA · 2023 · 300 citations · Full text

Systemic immune-inflammation index and bone mineral density in postmenopausal women: A cross-sectional study of the national health and nutrition examination survey (NHANES) 2007-2018

Yuchen Tang, Bo Peng, Jinmin Liu et al. · Frontiers in Immunology · 2022 · 175 citations · Full text

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit

Jie Wang, Keke Fei, Jing Hua et al. · mAbs · 2019 · 148 citations · Full text

Immunology, Immunoediting, Pathology +24

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Jianming Xu, Yi Li, Qingxia Fan et al. · Nature Communications · 2022 · 147 citations · Full text